Gastrointestinal Oncology

Genitourinary Oncology

Liver Oncology

Lymphoma

Neuroendocrine Tumors
The Connects

Learn more about the connect groups
on theconnects.info

Educational Programmes

The Educational Programmes on this page cover the following items:

Useful resources

Understanding the changing treatment landscape in HCC

Dr. Richard Finn, Dr. Amit Singal and Dr. Catherine Frenette discuss the topic ‘Understanding the changing treatment landscape in HCC and optimising therapy for the individual patient’. Please click on the link to watch the video and download the slides.

Go to Programme

EASL 2018

Update of EASL guidelines on management of HCC 2018

Dr. Catherine Frenette discusses the recently updated EASL clinical practice guidelines on the management of hepatocellular carcinoma (HCC).

Go to Programme

EASL 2017

HCC highlights from EASL 2017

Go to Programme

HCC CONNECT Update from…

AASLD 2018

HCC CONNECT Update From AASLD 2018

HCC CONNECT has summarised the highlights of AASLD 2018

Go to Programme

ILCA 2018

HCC CONNECT Update from ILCA 2018

HCC CONNECT has summarised the highlights of ILCA 2018

Go to Programme

ESMO 2018

HCC CONNECT Update from ESMO 2018

HCC CONNECT has summarised the highlights from ESMO 2018 for you

Go to Programme

AASLD & ILCA 2017

HCC CONNECT Update from Seoul and Washington DC

HCC CONNECT has summarised the highlights of ILCA 2017 and AASLD 2017.

Go to Programme

ESMO 2017

A CONNECT Update from Madrid

HCC CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.

Go to Programme

EASL 2017

HCC CONNECT Update from Amsterdam

HCC CONNECT has summarised the highlights of EASL 2017 for you.

Go to Programme

HCC CONNECT update from Boston

HCC CONNECT has summarised the highlights of the recent congress of the American Association for the Study of Liver Diseases (AASLD) 2016 in Boston for you.

Go to Programme

Your clinical questions answered

Please submit your clinical topic for the next HCC CONNECT newsletter here.

Advances in risk factors for HCC

Dr. Sammy Saab looks at the advances in risk factors for HCC.

Go to Programme

Is there a difference in liver cancer rates in patients who receive treatment for hepatitis?

Dr. Sammy Saab discusses the clinical question: Is there a difference in liver cancer rates in patients who receive treatment for hepatitits?

Go to Programme

Sequencing of HCC treatment

Dr. Amit Singal discusses recent data on Sequencing of HCC Treatment.

Go to Programme

What is the best approach for trans-arterial therapy in HCC?

Dr. Alexander Kim discusses the clinical question: What is the best approach for trans-arterial therapy in HCC?

Go to Programme

HCC screening for early diagnosis: feasibility and reality?

Dr. Catherine Frenette discusses the Clinical Question: HCC screening for early diagnosis: feasibility and reality?

Go to Programme

Relevant papers discussed

Sequential sorafenib and regorafenib in patients with advanced HCC

Dr. Mohamed Bouattour discusses the recently published additional analyses from the phase 3 RESORCE trial on sequential treatment with sorafenib followed by regorafenib for hepatocellular carcinoma.

Go to Programme

SIRT or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials

Dr. Mohamed Bouattour from Hôpital Beaujon, APHP Clichy, France, discusses the SARAH and SIRveNIB trials in locally advanced HCC

Go to Programme

The SARAH study in advanced HCC: implications for clinical practice

An overview of the SARAH study in advanced HCC is provided by Dr. Mohamed Bouattour.

Go to Programme